Ethyltrifluoromethylaminoindane

From WikiMD's WELLNESSPEDIA

Ethyltrifluoromethylaminoindane (ETAI) is a research chemical belonging to the aminoindane class. It is structurally related to compounds such as MDAI and 5-IAI, which are known for their psychoactive properties.

Chemistry[edit]

Ethyltrifluoromethylaminoindane is a synthetic molecule of the aminoindane class. Molecules of this class contain a indane group, which is a bicyclic structure consisting of a six-membered benzene ring fused to a five-membered nitrogen-containing ring. The "aminoindane" part of "ethyltrifluoromethylaminoindane" refers to the presence of an amino group (NH2) bound to the carbon of the five-membered indane ring.

Pharmacology[edit]

The pharmacological properties of ethyltrifluoromethylaminoindane are not well-studied. However, it is known that many aminoindanes act as monoamine releasers, increasing the levels of serotonin, dopamine, and norepinephrine in the brain. This can lead to stimulant effects, as well as empathogenic effects similar to those of MDMA.

Legal Status[edit]

The legal status of ethyltrifluoromethylaminoindane varies by country. In some countries, it is a controlled substance, while in others it is legal to possess for personal use.

Safety[edit]

As a research chemical, the safety profile of ethyltrifluoromethylaminoindane is largely unknown. It is recommended that users take caution when using this substance, due to the potential for adverse effects and the lack of information on long-term use.

See Also[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.